WEKO3
アイテム
Clinical implication of HLA class I expression in breast cancer
http://hdl.handle.net/10232/20319
http://hdl.handle.net/10232/20319580f1edc-dd8d-405c-8a7d-8c5393edda07
| 名前 / ファイル | ライセンス | アクション |
|---|---|---|
Clinical implication of HLA class I expression in breast cancer.pdf (953.6 kB)
|
|
| Item type | 学術雑誌論文 / Journal Article(1) | |||||
|---|---|---|---|---|---|---|
| 公開日 | 2014-01-30 | |||||
| タイトル | ||||||
| タイトル | Clinical implication of HLA class I expression in breast cancer | |||||
| タイトル言語 | en | |||||
| 著者 |
金子, 公一
× 金子, 公一× 石神, 純也× 喜島, 祐子× 舩迫, 和× 平田, 宗嗣× 奥村, 浩× 新地, 洋之× 郡山, 千早× 上野, 真一× 吉中, 平次× 夏越, 祥次 |
|||||
| 言語 | ||||||
| 言語 | eng | |||||
| キーワード | ||||||
| 主題言語 | en | |||||
| 主題Scheme | Other | |||||
| 主題 | HLA class I | |||||
| キーワード | ||||||
| 主題言語 | en | |||||
| 主題Scheme | Other | |||||
| 主題 | survival | |||||
| キーワード | ||||||
| 主題言語 | en | |||||
| 主題Scheme | Other | |||||
| 主題 | T cell immunology | |||||
| キーワード | ||||||
| 主題言語 | en | |||||
| 主題Scheme | Other | |||||
| 主題 | antitumor activity | |||||
| 資源タイプ | ||||||
| 資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||
| 資源タイプ | journal article | |||||
| 要約 | ||||||
| 内容記述タイプ | Other | |||||
| 内容記述 | Background: Human leukocyte antigen (HLA)-class I molecules on tumor cells have been regarded as crucial sites where cytotoxic T lymphocytes (CTL) can recognize tumor-specific antigens and are strongly associated with antitumor activity. However, the clinical impact of HLA class I expression in breast cancer has not been clarified. Methods: A total of 212 breast cancer patients who received curative surgery from 1993 to 2003 were enrolled in the current study. HLA class I expression was examined immunohistochemically using an anti-HLA class I monoclonal antibody. The correlation between HLA class I positivity and clinical factors was analyzed. Results: The downregulation of HLA class I expression in breast cancer was observed in 69 patients (32.5%). HLA class I downregulation was significantly associated with nodal involvement (p < 0.05), TNM stage (p < 0.05), lymphatic invasion (p < 0.01), and venous invasion (p < 0.05). Patients with preserved HLA class I had significantly better disease-free interval (DFI) than those with loss of HLA class I (p < 0.05). However, in multivariable analysis, HLA class I was not selected as one of the independent prognostic factors of disease-free interval. Conclusion: The examination of HLA class I expression is useful for the prediction of tumor progression and recurrent risk of breast cancer via the antitumor immune system. |
|||||
| 内容記述言語 | en | |||||
| 収録雑誌名 |
en : BMC Cancer 巻 11, p. 454, 発行日 2011 |
|||||
| 作成日 | ||||||
| 日付 | 2011-10-20 | |||||
| 日付タイプ | Issued | |||||
| ISSN | ||||||
| 収録物識別子タイプ | EISSN | |||||
| ISSN | 14712407 | |||||
| DOI | ||||||
| 識別子タイプ | DOI | |||||
| DOI | https://doi.org/10.1186/1471-2407-11-454 | |||||
| 権利 | ||||||
| 権利情報の言語 | en | |||||
| 権利情報 | (C) 2011 Kaneko et al; licensee BioMed Central Ltd. | |||||
| 出版タイプ | ||||||
| 出版タイプ | VoR | |||||
| 出版タイプResource | http://purl.org/coar/version/c_970fb48d4fbd8a85 | |||||
| NDC | ||||||
| 主題Scheme | NDC | |||||
| 主題 | 495 | |||||
| 公開者・出版者 | ||||||
| 出版者 | BioMed Central | |||||
| 出版者言語 | en | |||||
